Shopping Cart

Your shopping cart is currently empty

FX-11

Name: FX-11
Brand: TargetMol
SKU: T15362
Price: 41 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: LDHA Inhibitor FX11) Copy Product Info

😃Good

Synonyms: LDHA Inhibitor FX11

Catalog No. T15362 Copy Product Info

Purity: 98.95%

😃Good

FX-11 (LDHA Inhibitor FX11) is a highly potent, selective, and competitive inhibitor of lactate dehydrogenase A (LDHA), with a Ki value of 8 μM for LDHA. FX-11 acts as an activator of PKM2 (pyruvate kinase M2). FX-11 exerts its antitumor effects by inhibiting glycolysis, depleting ATP, and inducing oxidative stress and apoptosis. FX-11 can be used in tumor metabolism research.

Cas No. 213971-34-7

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$41	In Stock	In Stock
5 mg	$98	In Stock	In Stock
10 mg	$142	In Stock	In Stock
25 mg	$236	In Stock	In Stock
50 mg	$348	In Stock	In Stock
100 mg	$520	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$107	In Stock	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:98.95%

Appearance:Solid

Color:Yellow to Brown

Resource Download

COA HNMR HPLC

Product Introduction

Bioactivity

Description	FX-11 (LDHA Inhibitor FX11) is a highly potent, selective, and competitive inhibitor of lactate dehydrogenase A (LDHA), with a Ki value of 8 μM for LDHA. FX-11 acts as an activator of PKM2 (pyruvate kinase M2). FX-11 exerts its antitumor effects by inhibiting glycolysis, depleting ATP, and inducing oxidative stress and apoptosis. FX-11 can be used in tumor metabolism research.
Targets & IC50	LDHA:8 μM (Ki), LDHA (HeLa cells):23.3 μM, PC3 cells:27 ± 1.1 μM, DU-145 cells:32 ± 1.1 μM
In vitro	Methods: Human breast cancer cells (MCF-7) were cultured under normoxic and hypoxic conditions. Cells were treated with the inhibitor FX-11 at half-logarithmic dilution concentrations (200, 100, 50, 25, 12.5, 0 μM) for 24 hours. Cell viability was assessed using the AlamarBlue assay. Results: FX-11 monotherapy: Inhibited cancer cell proliferation under both normoxic and hypoxic conditions. [1] Methods: Human umbilical vein endothelial cells (HUVEC) were treated with FX-11 (20 μM). After 2 hours, cells were stimulated with LPS (200 ng/mL) for 24 hours to induce inflammation. Immunoblotting was used to detect HIF-1α and LDHA expression levels. Results: FX-11 treatment significantly suppressed LPS-induced upregulation of HIF-1α and LDHA protein expression. [2]
In vivo	Methods: C57BL/6J mice were administered FX-11 (10 mg/kg) via intraperitoneal injection. Two hours later, LPS (20 mg/kg) was administered intraperitoneally to induce an acute lung injury model of sepsis. Tissue samples were collected and analyzed after 24 hours. Results: FX-11 pretreatment significantly attenuated LPS-induced pathological damage in lung tissue and markedly reduced HIF-1α and LDHA protein levels in lung tissue. [2]
Synonyms	LDHA Inhibitor FX11

Chemical Properties

Molecular Weight	350.41
Formula	C₂₂H₂₂O₄
Cas No.	213971-34-7
Smiles	CCCc1c(O)c(O)c(C(O)=O)c2cc(Cc3ccccc3)c(C)cc12
Relative Density.	1.260 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Store at low temperature,Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 260 mg/mL (741.99 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (14.27 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.8538 mL	14.2690 mL	28.5380 mL	142.6900 mL
5 mM	0.5708 mL	2.8538 mL	5.7076 mL	28.5380 mL
10 mM	0.2854 mL	1.4269 mL	2.8538 mL	14.2690 mL
20 mM	0.1427 mL	0.7134 mL	1.4269 mL	7.1345 mL
50 mM	0.0571 mL	0.2854 mL	0.5708 mL	2.8538 mL
100 mM	0.0285 mL	0.1427 mL	0.2854 mL	1.4269 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.